Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Breast Cancer

Free Subscription 22.10.2018 1 Am J Epidemiol 2 Ann Surg Oncol 2 BMC Cancer 5 Br J Cancer 4 Breast Cancer 1 Breast Cancer (Dove Med Press) 1 Breast Cancer Res 10 Breast Cancer Res Treat 5 Cancer 1 Cancer Lett 1 Cancer Res 2 Carcinogenesis 1 Clin Breast Cancer 2 Clin Cancer Res 1 Clin Exp Metastasis 1 Eur J Surg Oncol 3 Int J Oncol 1 J Surg Oncol 1 Lancet Oncol 1 Mod Pathol 2 Oncol Rep 1 PLoS One 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Am J Epidemiol

1. RYSER MD, Gulati R, Eisenberg MC, Shen Y, et al
   Identification of the Fraction of Indolent Tumors and Associated Overdiagnosis in Breast Cancer Screening Trials.
   Am J Epidemiol. 2018 Oct 16. pii: 5133242. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   

   
   Ann Surg Oncol

2. HILAL T, Patel BK
   ASO Author Reflections: Role of Contrast-Enhanced Spectral Mammography in the Assessment of Residual Breast Cancer After Neoadjuvant Systemic Therapy.
   Ann Surg Oncol. 2018 Oct 15. pii: 10.1245/s10434-018-6899.
   PubMed     Text format    
   
   
3. WEISS A
   ASO Author Reflections: Reconstruction in the Metastatic Breast Cancer Patient-Shifting Focus to Quality of Life.
   Ann Surg Oncol. 2018 Oct 15. pii: 10.1245/s10434-018-6911.
   PubMed     Text format    
   
   

   
   BMC Cancer

4. LI L, Chang B, Jiang X, Fan X, et al
   Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer.
   BMC Cancer. 2018;18:977.
   PubMed     Text format     Abstract available
   
   
5. ARAKI K, Ito Y, Fukada I, Kobayashi K, et al
   Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel.
   BMC Cancer. 2018;18:982.
   PubMed     Text format     Abstract available
   
   

   
   Br J Cancer

6. MEURS CJC, van Rosmalen J, Menke-Pluijmers MBE, Ter Braak BPM, et al
   A prediction model for underestimation of invasive breast cancer after a biopsy diagnosis of ductal carcinoma in situ: based on 2892 biopsies and 589 invasive cancers.
   Br J Cancer. 2018 Oct 17. pii: 10.1038/s41416-018-0276.
   PubMed     Text format     Abstract available
   
   
7. O'CARRIGAN B, Lim JSJ, Jalil A, Harris SJ, et al
   Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre.
   Br J Cancer. 2018 Oct 15. pii: 10.1038/s41416-018-0290.
   PubMed     Text format     Abstract available
   
   
8. CHAKRABORTY S, Jiang C, Gau D, Oddo M, et al
   Profilin-1 deficiency leads to SMAD3 upregulation and impaired 3D outgrowth of breast cancer cells.
   Br J Cancer. 2018 Oct 15. pii: 10.1038/s41416-018-0284.
   PubMed     Text format     Abstract available
   
   
9. SCIMECA M, Urbano N, Bonfiglio R, Schillaci O, et al
   Breast osteoblast-like cells: a new biomarker for the management of breast cancer.
   Br J Cancer. 2018 Oct 17. pii: 10.1038/s41416-018-0255.
   PubMed     Text format     Abstract available
   
   
10. JOHNS LE, Jones ME, Schoemaker MJ, McFadden E, et al
    Response to 'Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study".
    Br J Cancer. 2018 Oct 17. pii: 10.1038/s41416-018-0177.
    PubMed     Text format    
    
    

    
    Breast Cancer

11. IIDA M, Tsuboi K, Niwa T, Ishida T, et al
    Compensatory role of insulin-like growth factor 1 receptor in estrogen receptor signaling pathway and possible therapeutic target for hormone therapy-resistant breast cancer.
    Breast Cancer. 2018 Oct 16. pii: 10.1007/s12282-018-0922.
    PubMed     Text format     Abstract available
    
    
12. TSURUTANI J, Sakata Y, Matsuoka T
    Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study.
    Breast Cancer. 2018 Oct 15. pii: 10.1007/s12282-018-0919.
    PubMed     Text format     Abstract available
    
    
13. SUZUKI E, Sugimoto M, Kawaguchi K, Pu F, et al
    Gene expression profile of peripheral blood mononuclear cells may contribute to the identification and immunological classification of breast cancer patients.
    Breast Cancer. 2018 Oct 13. pii: 10.1007/s12282-018-0920.
    PubMed     Text format     Abstract available
    
    
14. KWAPISZ D
    Oligometastatic breast cancer.
    Breast Cancer. 2018 Oct 15. pii: 10.1007/s12282-018-0921.
    PubMed     Text format     Abstract available
    
    

    
    Breast Cancer (Dove Med Press)

15. DIGESU C, Deodato F, Macchia G, Cilla S, et al
    Hypofractionated radiotherapy after conservative surgery may increase low-intermediate grade late fibrosis in breast cancer patients.
    Breast Cancer (Dove Med Press). 2018;10:143-151.
    PubMed     Text format     Abstract available
    
    

    
    Breast Cancer Res

16. BORGEN E, Rypdal MC, Sosa MS, Renolen A, et al
    NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients.
    Breast Cancer Res. 2018;20:120.
    PubMed     Text format     Abstract available
    
    

    
    Breast Cancer Res Treat

17. HWANG HW, Jung H, Hyeon J, Park YH, et al
    A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients.
    Breast Cancer Res Treat. 2018 Oct 15. pii: 10.1007/s10549-018-4981.
    PubMed     Text format     Abstract available
    
    
18. SOPIK V, Sun P, Narod SA
    Predictors of time to death after distant recurrence in breast cancer patients.
    Breast Cancer Res Treat. 2018 Oct 16. pii: 10.1007/s10549-018-5002.
    PubMed     Text format     Abstract available
    
    
19. LEONARDIS JM, Diefenbach BJ, Lyons DA, Olinger TA, et al
    The influence of reconstruction choice and inclusion of radiation therapy on functional shoulder biomechanics in women undergoing mastectomy for breast cancer.
    Breast Cancer Res Treat. 2018 Oct 16. pii: 10.1007/s10549-018-5003.
    PubMed     Text format     Abstract available
    
    
20. CAIN EH, Saha A, Harowicz MR, Marks JR, et al
    Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set.
    Breast Cancer Res Treat. 2018 Oct 16. pii: 10.1007/s10549-018-4990.
    PubMed     Text format     Abstract available
    
    
21. FASCHING PA, Hartkopf AD, Gass P, Haberle L, et al
    Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis.
    Breast Cancer Res Treat. 2018 Oct 15. pii: 10.1007/s10549-018-5008.
    PubMed     Text format     Abstract available
    
    
22. INNO A, Barni S, Ghidini A, Zaniboni A, et al
    One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2018 Oct 13. pii: 10.1007/s10549-018-5001.
    PubMed     Text format     Abstract available
    
    
23. HENNIGS A, Kopke M, Feisst M, Riedel F, et al
    Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?
    Breast Cancer Res Treat. 2018 Oct 12. pii: 10.1007/s10549-018-5009.
    PubMed     Text format     Abstract available
    
    
24. TERADA M
    Challenge for identifying the origin of occult breast cancer for optimizing local therapy.
    Breast Cancer Res Treat. 2018 Oct 15. pii: 10.1007/s10549-018-4931.
    PubMed     Text format    
    
    
25. ALTUNDAG K
    Better pathological tumor characteristics might occur in recurrent metastatic breast cancer patients after 10-year metastatic free interval.
    Breast Cancer Res Treat. 2018 Oct 15. pii: 10.1007/s10549-018-5011.
    PubMed     Text format    
    
    
26. ASTASHCHANKA A, Shroka TM, Jacobsen BM
    Mucin 2 (MUC2) modulates the aggressiveness of breast cancer.
    Breast Cancer Res Treat. 2018 Oct 13. pii: 10.1007/s10549-018-4989.
    PubMed     Text format     Abstract available
    
    

    
    Cancer

27. HOSKINS KF, Tejeda S, Vijayasiri G, Chukwudozie IB, et al
    A feasibility study of breast cancer genetic risk assessment in a federally qualified health center.
    Cancer. 2018 Oct 15. doi: 10.1002/cncr.31635.
    PubMed     Text format     Abstract available
    
    
28. LANDEIRO LCG, Gagliato DM, Fede AB, Fraile NM, et al
    Return to work after breast cancer diagnosis: An observational prospective study in brazil.
    Cancer. 2018 Oct 17. doi: 10.1002/cncr.31735.
    PubMed     Text format     Abstract available
    
    
29. 
    MINDACT study results show low risk of local recurrence after 5 years for patients with early breast cancer.
    Cancer. 2018;124:3466-3467.
    PubMed     Text format    
    
    
30. 
    First person: George Sledge, Jr, MD: Former ASCO president leads breast cancer research and mentors Stanford faculty.
    Cancer. 2018;124:3465.
    PubMed     Text format    
    
    
31. ROCQUE GB, Williams CP, Kenzik KM, Jackson BE, et al
    Concordance with NCCN treatment guidelines: Relations with health care utilization, cost, and mortality in breast cancer patients with secondary metastasis.
    Cancer. 2018 Oct 14. doi: 10.1002/cncr.31694.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Lett

32. DING J, Wang X, Zhang Y, Sang X, et al
    Inhibition of BTF3 sensitizes luminal breast cancer cells to PI3Kalpha inhibition through the transcriptional regulation of ERalpha.
    Cancer Lett. 2018 Oct 10. pii: S0304-3835(18)30605.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Res

33. 
    Correction: Absence of the Full-Length Breast Cancer-Associated Gene-1 Leads to Increased Expression of Insulin-Like Growth Factor Signaling Axis Members.
    Cancer Res. 2018;78:6025.
    PubMed     Text format    
    
    

    
    Carcinogenesis

34. HAO S, Chen X, Wang F, Shao Q, et al
    Breast cancer cells-derived IL-35 promotes tumor progression via induction of IL-35-producing induced regulatory T cells.
    Carcinogenesis. 2018 Oct 13. pii: 5128955. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
35. GONG Z, Wang J, Wang D, Buas MF, et al
    Differences in microRNA expression in breast cancer between women of African and European ancestry.
    Carcinogenesis. 2018 Oct 13. pii: 5128950. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    

    
    Clin Breast Cancer

36. MCGEE SF, Vandermeer L, Mazzarello S, Sienkiewicz M, et al
    Physician Survey of Timing of Adjuvant Endocrine Therapy Relative to Radiotherapy in Early Stage Breast Cancer Patients.
    Clin Breast Cancer. 2018 Sep 4. pii: S1526-8209(18)30204.
    PubMed     Text format     Abstract available
    
    

    
    Clin Cancer Res

37. VELDWIJK MR, Seibold P, Botma A, Helmbold I, et al
    Association of CD4(+) radiation-induced lymphocyte apoptosis with fibrosis and telangiectasia after radiotherapy in 272 breast cancer patients with >10-year follow-up.
    Clin Cancer Res. 2018 Oct 16. pii: 1078-0432.CCR-18-0777.
    PubMed     Text format     Abstract available
    
    
38. CROESSMANN S, Formisano L, Kinch L, Gonzalez-Ericsson PI, et al
    Combined blockade of activating ERBB2 mutations and ER results in synthetic lethality of ER+/HER2 mutant breast cancer.
    Clin Cancer Res. 2018 Oct 12. pii: 1078-0432.CCR-18-1544.
    PubMed     Text format     Abstract available
    
    

    
    Clin Exp Metastasis

39. LIEDTKE C, Kolberg HC, Kerschke L, Gorlich D, et al
    Systematic analysis of parameters predicting pathological axillary status (ypN0 vs. ypN+) in patients with breast cancer converting from cN+ to ycN0 through primary systemic therapy (PST).
    Clin Exp Metastasis. 2018 Oct 15. pii: 10.1007/s10585-018-9938.
    PubMed     Text format     Abstract available
    
    

    
    Eur J Surg Oncol

40. DOROGI B, Bukovszky B, Matrai T, Savolt A, et al
    Mapping of the functional anatomy of lymphatic drainage to the axilla in early breast cancer: A cohort study of 933 cases.
    Eur J Surg Oncol. 2018 Oct 7. pii: S0748-7983(18)31418.
    PubMed     Text format     Abstract available
    
    

    
    Int J Oncol

41. LU H, Chen J, Luo Y, Xu H, et al
    Curcolonol suppresses the motility of breast cancer cells by inhibiting LIM kinase 1 to downregulate cofilin 1 phosphorylation.
    Int J Oncol. 2018 Oct 10. doi: 10.3892/ijo.2018.4592.
    PubMed     Text format     Abstract available
    
    
42. SHAO YC, Nie XC, Song GQ, Wei Y, et al
    Prognostic value of DKK2 from the Dickkopf family in human breast cancer.
    Int J Oncol. 2018 Oct 9. doi: 10.3892/ijo.2018.4588.
    PubMed     Text format     Abstract available
    
    
43. GAO Y, Liu H, Wang H, Hu H, et al
    Baicalin inhibits breast cancer development via inhibiting IkB kinase activation in vitro and in vivo.
    Int J Oncol. 2018 Oct 12. doi: 10.3892/ijo.2018.4594.
    PubMed     Text format     Abstract available
    
    

    
    J Surg Oncol

44. HO OA, Lin YL, Pappalardo M, Cheng MH, et al
    Nipple-sparing mastectomy and breast reconstruction with a deep inferior epigastric perforator flap using thoracodorsal recipient vessels and a low lateral incision.
    J Surg Oncol. 2018;118:621-629.
    PubMed     Text format     Abstract available
    
    

    
    Lancet Oncol

45. YAFFE MJ
    Towards improving accuracy, effectiveness, and efficiency in breast cancer screening.
    Lancet Oncol. 2018 Oct 12. pii: S1470-2045(18)30589.
    PubMed     Text format    
    
    

    
    Mod Pathol

46. CLARK BZ, Onisko A, Assylbekova B, Li X, et al
    Breast cancer global tumor biomarkers: a quality assurance study of intratumoral heterogeneity.
    Mod Pathol. 2018 Oct 16. pii: 10.1038/s41379-018-0153.
    PubMed     Text format     Abstract available
    
    

    
    Oncol Rep

47. YU Z, Lou L, Zhao Y
    Fibroblast growth factor 18 promotes the growth, migration and invasion of MDAMB231 cells.
    Oncol Rep. 2018;40:704-714.
    PubMed     Text format     Abstract available
    
    
48. ZHAO Y, Onda K, Sugiyama K, Yuan B, et al
    Antitumor effects of arsenic disulfide on the viability, migratory ability, apoptosis and autophagy of breast cancer cells.
    Oncol Rep. 2018 Oct 9. doi: 10.3892/or.2018.6780.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

49. HARALDSDOTTIR A, Torfadottir JE, Valdimarsdottir UA, Adami HO, et al
    Correction: Dietary habits in adolescence and midlife and risk of breast cancer in older women.
    PLoS One. 2018;13:e0206026.
    PubMed     Text format     Abstract available
    
    

    
    Proc Natl Acad Sci U S A

50. ARVANITIS CD, Askoxylakis V, Guo Y, Datta M, et al
    Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood-tumor barrier disruption.
    Proc Natl Acad Sci U S A. 2018 Aug 27. pii: 1807105115.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: